PROKIDNEY CORP (PROK)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$1.85-7.04%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Quarterly revenue remains stable near $226K: rev $0.15M vs $220K target.
ProKidney is working to control losses and cash burn. Operating losses improved from -$51.6M to -$44.9M. Revenue is stable near $226K quarterly. The company aims to maintain funding into mid-2027.
ProKidney remains loss-making with negative EPS and cash flow. Revenue growth is stagnant near $217K-$226K. Litigation risks and ongoing cash burn threaten sustainability.
The market reflects uncertainty with no clear consensus revenue growth or fair value. Recent estimate revisions are slightly negative but improving. Our view sees risk in execution and funding.
Breaks if: funding runway falls short of mid-2027
Ensure sufficient cash, cash equivalents, and marketable securities to fund operating expenses and capital expenditures into mid-2027.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and has shown weak recent financial performance, but it operates in a sector with favorable tailwinds, which could support its long-term growth potential.
The market appears to be pricing in a high level of risk, given the company's recent earnings misses and ongoing cash burn. Expectations seem cautious, particularly as the company operates in a high-miss-rate industry.
Management remains stable but faces challenges in managing operating losses and cash burn. While they are on track with key clinical milestones, the trajectory for reducing losses is mixed and may impact future performance.
The long-term thesis hinges on the outcomes of the PROACT 1 trial and the ability to maintain funding through mid-2027. Additionally, broader sector performance and economic conditions, such as job growth, will be critical factors to monitor.
The most important moves since the prior daily snapshot.
Company momentum fell by 39.7 points (from -9.5 to -49.2).
Yes, our read has weakened. The latest earnings miss has negatively impacted the outlook. Recent financial performance remains weak, with quarterly revenue stable near $226K, below the target.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 of last 3 quarters. Cash and marketable securities decreased from $224.9 million in 2026-Q1 to $181.6 million in 2026-Q2 but remain sufficient to fund operations into mid-2027 as management has consistently stated. The trajectory shows delivering on maintaining runway despite cash burn.
“Ended Q2 2026 with $181.6 million in cash and marketable securities, supporting operations into mid-2027.”
“Cash, cash equivalents and marketable securities as of March 31, 2026, totaled $224.9 million, supporting operations into mid-2027.”
“Existing cash and marketable securities held on September 30, 2025, expected to fund operating expenses and capital expenditures into mid-2027.”
Breaks if: operating losses worsen beyond -$50M next quarter
Control operating expenses and net losses while managing cash flow to sustain operations.
Stated as a priority in 2 of last 2 quarters. Net loss before noncontrolling interest increased from $42.6 million in 2026-Q1 to $46.4 million in 2026-Q2, with operating losses rising from $44.9 million to $48.4 million. Cash from operating activities remains negative, indicating ongoing cash burn. The trajectory shows limited progress in reducing losses and cash burn.
“Net loss before noncontrolling interest was $46.4 million for Q2 2026.”
“Net loss before noncontrolling interest was $42.6 million for Q1 2026.”
Breaks if: quarterly revenue falls below $200K next quarter
In the 1 to 3 year view, PROK's future depends on clinical trial results and sector momentum, amidst a backdrop of significant risk. Not investment advice.